Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Respiratory disorder, SARS-CoV-2 antibody test, Skin disorder
Clinical narrative: she has been experiencing on going cardiovascular, respiratory, cognitive, musculoskeletal, neurologic and integumentary side effects; she has been experiencing on going cardiovascular, respiratory, cognitive, musculoskeletal, neurologic and integumentary side effects; she has been experiencing on going cardiovascular, respiratory, cognitive, musculoskeletal, neurologic and integumentary side effects; she has been experiencing on going cardiovascular, respiratory, cognitive, musculoskeletal, neurologic and integumentary side effects; she has been experiencing on going cardiovascular, respiratory, cognitive, musculoskeletal, neurologic and integumentary side effects; she has been experiencing on going cardiovascular, respiratory, cognitive, musculoskeletal, neurologic and integumentary side effects; This is a spontaneous report from a contactable consumer (Nurse-patient) via medical information team. A 48-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Lot Number: EJ1685), via an unspecified route of administration, administered in Deltoid Left on 22Dec2020 (at the age of 48-year-old), as 1st dose, single for covid-19 immunisation. Medical history included ongoing hyperlipidemia, ongoing vasomotor symptoms related to Menopause, ongoing allergic rhinitis and chronic allergy. Concomitant medications included Montelukast sodium (SINGULAIR) 10mg, once daily, Pravastatin sodium (PRAVACHOL) 20 mg once daily; Medroxyprogesterone acetate (PROVERA) 2.5 mg once daily and Estrogens conjugated (PREMARIN), all taken for an unspecified indication, start and stop date were not reported. Patient reported that Premarin cream, I think its I forget to measure that 0.5 was it grams. Vaginally, Its Premarin cream 0.5g vaginally and I think its 0.625. On 22Dec2020, within five minutes after vaccination, the patient experienced cardiovascular, respiratory, cognitive, musculoskeletal, neurologic, and integumentary side effects. The patient stated that she had for the first two months they worsened and then they have plateaued and were not improving. She had been out of work for three months. Investigation assessment was done. The patient lab tests included CBC, CMP, TSH, Sed Rate, CRP and then a Coronavirus Antibody test and the nucleocapsid antibody test, for all the tests the results were unknown. It was reported that everything was normal and there was no evidence of active antibodies produced from the COVID infection, which was what the nucleocapsid test showed. The CBC recommended that test to determine because she had symptoms consistent with long haulers, but she had no evidence of antibody from infection (Further clarification unknown). Reportedly, patient did not receive her second dose because she was experiencing ongoing side effects and stated that she will not. Patient asked if someone was going to check in with her periodically to see If symptoms are improving. Was Pfizer studying the people researching the people, that are having long term side effect.The patient stated that she did not take any treatment as there was no treatment to take, had not received medical care. She reported that she would not even get a doctor to see her at any of the tertiary care facility in her area. Patient wanted to report this just to make sure that Pfizer note that she experienced the side effect. It was reported that patient experienced cardiovascular, respiratory, Cognitive musculoskeletal, integumentary and neurologic side effect which were related to Pfizer-BioNTech COVID-19 Vaccine. Reporter seriousness was unspecified. The outcome of the events was unknown at the time of this report.  Information on Lot/Batch number was available. Additional information has been requested.